What happened
Moderna and Merck announced that their personalized mRNA cancer vaccine cut death and recurrence by 42% in melanoma (skin cancer) patients. The disclosure is based on results from the two companies' joint study.
Why it matters
Until now, mRNA technology has been associated mainly with vaccines against infectious diseases. This result is one of the clearest signs that the same approach could work in cancer treatment.
What is a personalized vaccine?
In these vaccines, mutations in a patient's tumor are analyzed and a custom mRNA mixture is prepared for that person. The goal is to guide the immune system to recognize and destroy cancer cells.
Limits
The shared information is headline-level; detailed patient data, side effects and approval-process specifics are not included in the source. Independent review of the results and regulatory scrutiny will shape what comes next.
